ASET Colloquium

Targeting targets: Has personalized medicine in cancer come of age?

by Dr. Hari Menon (Tata Memorial Hospital, Parel)

Friday, June 10, 2016 from to (Asia/Kolkata)
at AG-66
Description
The realm of cancer biology has witnessed an explosion in terms of understanding pathways that play a key role in in cancer cell growth, spread and survival. Perturbing these pathways using small molecules has spawned the science of “rational” drug designing with an objective of deriving best results with minimum toxicity. However the story of targeted therapy has been a mixed bag. While there has been immense success in dealing with a complex disease using designed approaches, the objective of “cure” has remained elusive. The redundancy of cancer pathways has been a bane to successful outcomes including durable responses. The perceived notion of minimal toxicity has also not sustained with emergence of unique issues due to interference with physiological processes. However these  problems notwithstanding understanding targets and exploiting them for benefit has brought in a paradigm shift in the way cancer is viewed and managed today.

About Dr. Hari Menon:

Dr. Hari Menon did his MBBS, MD (Internal Medicine) and DM (Medical Oncology) at Government Medical College Thiruvananthapuram, Seth.G.S. Medical College and King Edward Memorial Hospital Mumbai, and at the All India Institute of Medical Sciences New Delhi respectively. He published about 100 papers, conference proceedings and book chapters etc. He is deeply engaged in several  research projects and activities funded by the Indian and foreign establishments and hospitals. He is a reviewer of several medical journals - Indian Journal of Medical and Pediatric Oncology (IJMPO), Journal of Cancer Research Therapeutics (JCRT), Indian Journal of Cancer and Clinical Oncology, to name a few.


Material:
Slides powerpoint filedown arrow
Organised by Dr. Satyanarayana Bheesette
PODCAST click here to start